#USA #Zydus Lifesciences #Zynext Ventures #Pennington #Feldan Therapeutics

Zynext Ventures Invests in Feldan Therapeutics

Zynext Ventures USA LLC, the investment arm of Zydus Lifesciences, has recently made waves in the healthcare sector by announcing its investment in Feldan Therapeutics. This Canadian company is at the forefront of innovation, particularly in the realm of intracellular drug delivery technology.

Feldan specializes in delivering therapeutics directly into cells, utilizing its proprietary Shuttle peptide technology. This technology represents a leap forward in efficiently and accurately targeting biomolecules where they are needed most. One of Feldan's flagship products, FLD-103, is designed specifically for treating basal cell carcinoma (BCC). The way this product works is remarkable: the Shuttle peptide carries a Hedgehog inhibitor straight to cancerous cells within BCC lesions, potentially offering patients a non-surgical treatment option that improves health outcomes and enhances quality of life.

In addition to their dermatological advances, Feldan is also making strides in pulmonary therapeutics. Their innovative approach looks to harness the Shuttle peptide's unique ability to deliver biomolecules into the challenging matrix of lung cells, targeting unmet medical needs in respiratory diseases.

Dr. Sharvil Patel, MD of Zydus Lifesciences, expressed enthusiasm about the collaboration, stating, "At Zydus, we are dedicated to advancing novel therapeutics that tackle critical healthcare gaps through innovative solutions. Our support for Feldan reflects our commitment to offering targeted, safe options for patients suffering from dermatological and pulmonary diseases, ultimately helping them lead better lives."

This investment marks a significant milestone for Zynext Ventures as well, with Director Jay Kothari emphasizing that Feldan's platform could revolutionize intracellular delivery systems and pave the way for next-generation therapeutics. His vision aligns with Zynext’s strategy to foster and support disruptive innovations in the pharmaceutical space.

Expressing his views on the partnership, François-Thomas Michaud, CEO of Feldan Therapeutics, highlighted the excitement that this collaboration brings. He stated, "The partnership with Zynext Ventures represents a significant advancement in our commitment to improve patients' lives and effectively address the significant challenges associated with drug delivery. With the support of Zynext Ventures, we are well-equipped to accelerate our development of groundbreaking therapies."

About Zynext Ventures

Zynext Ventures, a member of the Zydus Lifesciences family, is committed to identifying and supporting early-stage and growth-stage companies within the healthcare sector. Their goal is to provide not just financial backing, but also strategic guidance and industry knowledge to help their partners achieve remarkable successes that can genuinely impact patients' lives.

About Zydus Lifesciences

Zydus Lifesciences Ltd. is a global lifesciences powerhouse aimed at empowering individuals to live healthier lives. With over 27,000 employees worldwide, including 1,400 dedicated scientists, Zydus continually pushes the boundaries of healthcare innovation. Their mission is to unlock new opportunities in life sciences through quality healthcare solutions that genuinely affect individuals and communities.

For further details, visit Zynext Ventures and Zydus Lifesciences.